期刊
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
卷 18, 期 3, 页码 230-241出版社
HARBORSIDE PRESS
DOI: 10.6004/jnccn.2020.0012
关键词
-
类别
资金
- AstraZeneca
- Celgene Corporation
- Coherus BioSciences
- Genentech, a member of the Roche Group
- TESARO, a GSK Company
- Bayer Healthcare Pharmaceuticals
- Bristol-Myers Squibb
- Exelixis, Inc.
- Merck Co., Inc.
The NCCN Guidelines for Management of Immunotherapy-Related Toxicities provide interdisciplinary guidance on the management of immune-related adverse events (irAEs) resulting from cancer immunotherapy. These NCCN Guidelines Insights describe symptoms that may be caused by an irAE and should trigger further investigation, and summarize the NCCN Management of Immunotherapy-Related Toxicities Panel discussions for the 2020 update to the guidelines regarding immune checkpoint inhibitor-related diarrhea/colitis and cardiovascular irAEs.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据